Effects of rosuvastatin treatment and other statins on burn wound healing

Burn injuries represent a significant global public health concern and can result in severe complications. The process of burn wound recovery is intricate, dynamic and involves a series of synchronized events, such as hemostasis, inflammation, proliferation, revascularization, and remodeling. Obstacles in the healing of burn wounds are widespread, both in community and hospital settings. The correlation between the delay in wound-healing of burn injuries with increased mortality rates has led numerous investigators to devise novel therapeutic approaches aimed at accelerating the recovery of burn wounds. Statins, recognized for their varied pleiotropic impacts, have been proposed to enhance wound healing. Insights drawn from studies involving both animals and humans show that statins can speed up wound recovery. Rosuvastatin is one of the most recently studied statins. It promotes wound healing due to its hydrophilic characteristics, in combination with high hepatoselectivity and long half-life, which enable targeted action on the endothelium, improving microcirculation and promoting angiogenesis. Despite the encouraging preliminary results, it has not been widely used, resulting in limited data and heterogeneity. However, further high-quality, evidence-based research is urgently needed to identify whether rosuvastatin may present clinical advantages and improve burn wound recovery through angiogenesis, lymph-angiogenesis and microvascular function. Thus, rosuvastatin could be a potential alternative therapeutic approach for treating burn wounds.